中国创新药国际化跨越:从“规模积累”走向“价值释放”2017 至2026 年是国产药企实力获全球认可的“黄金十年”。中国创新药License-out交易总包从2017 年的25.62 亿美元飙升至2025 年的1402.74 亿美元,实现指数级跨越。2026 年以重磅BD 强势开年,年初License-out 交易首付款总额已超2025 年的39%,总包总额已达2025 年的22%,充分印证了中国...
Source Link中国创新药国际化跨越:从“规模积累”走向“价值释放”2017 至2026 年是国产药企实力获全球认可的“黄金十年”。中国创新药License-out交易总包从2017 年的25.62 亿美元飙升至2025 年的1402.74 亿美元,实现指数级跨越。2026 年以重磅BD 强势开年,年初License-out 交易首付款总额已超2025 年的39%,总包总额已达2025 年的22%,充分印证了中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.